EUVIMEDEUVIMED entdecken
Crossref

Formulation Of Eudragit Based Sulfasalazine Nanosuspension With Enhanced Drug Encapsulation

Kunal A Suryawanshi, Kiran B Erande, Dinesh P Patil, Yash S Bachhav, Pratiksha P Nahar, Shubham P Bagad, Mangesh P Ubale, Yuvraj S Jadhav, Aditi P Bhalerao, Avishkar B Patil, Nikhat P A Iqball, Amol V Pawar

International Journal of Drug Delivery Technology · 14.04.2026 · 16 (9s)

DOI: 10.25258/ijddt.16.9s.100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 14.04.2026. Verfasst von Kunal A Suryawanshi und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study focuses on the development and optimization of a novel sulfasalazine nanosuspension for the treatment of inflammatory bowel disease, particularly ulcerative colitis. Sulfasalazine-loaded nanoparticles were formulated using Eudragit RS 100 polymer and optimized through a 3-level factorial design employing Design-Expert software. The primary objective was to achieve nanoparticles with minimal particle size and polydispersity index (PDI), and maximum entrapment efficiency (%EE). The software predicted a particle size of 234 nm and %EE of 83.89% with a desirability of 0.476. The optimized formulation exhibited a particle size of 228 nm, PDI of 0.263, and %EE of 84.46%, closely matching the predicted values. Zeta potential analysis showed a high negative value of -40.8 mV, indicating excellent colloidal stability. Characterization studies including DSC, FTIR, and XRD confirmed good physicochemical compatibility and successful drug encapsulation. TEM analysis revealed uniform and well-defined nanoparticles in the first image, while the second image showed some aggregation, suggesting morphological variability. The formulation's viscosity and pH were within acceptable ranges, and drug content analysis confirmed uniform distribution in the hydrogel. In-vitro drug release studies demonstrated sustained release of sulfasalazine over 12–24 hours, attributed to the polymer’s controlled-release properties. the developed sulfasalazine nanosuspension presents a promising and superior therapeutic strategy for the effective management of ulcerative colitis.

Zitieren

APA

Suryawanshi, K. A., Erande, K. B., Patil, D. P., Bachhav, Y. S., Nahar, P. P., Bagad, S. P., Ubale, M. P., Jadhav, Y. S., Bhalerao, A. P., Patil, A. B., Iqball, N. P. A., & Pawar, A. V. (2026). Formulation Of Eudragit Based Sulfasalazine Nanosuspension With Enhanced Drug Encapsulation. International Journal of Drug Delivery Technology, 16(9s). https://doi.org/10.25258/ijddt.16.9s.100

Vancouver

Suryawanshi KA, Erande KB, Patil DP, Bachhav YS, Nahar PP, Bagad SP, et al. Formulation Of Eudragit Based Sulfasalazine Nanosuspension With Enhanced Drug Encapsulation. International Journal of Drug Delivery Technology. 2026;16(9s). doi:10.25258/ijddt.16.9s.100

BibTeX
@article{Suryawanshi2026,
  author = {Suryawanshi, Kunal A and Erande, Kiran B and Patil, Dinesh P and Bachhav, Yash S and Nahar, Pratiksha P and Bagad, Shubham P and Ubale, Mangesh P and Jadhav, Yuvraj S and Bhalerao, Aditi P and Patil, Avishkar B and Iqball, Nikhat P A and Pawar, Amol V},
  title = {Formulation Of Eudragit Based Sulfasalazine Nanosuspension With Enhanced Drug Encapsulation},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {9s},
  doi = {10.25258/ijddt.16.9s.100}
}
Kostenlos starten →